Cannabis based drugs: GPs should be able to prescribe to improve access, NICE says
BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l5107 (Published 09 August 2019) Cite this as: BMJ 2019;366:l5107- Ingrid Torjesen
- London
GPs and other prescribers such as pharmacists and nurses should be able to take on prescribing of cannabis based medicinal products once it has been initiated by specialists in expert centres, the UK National Institute for Health and Care Excellence has proposed in draft guidance.1
Expanding prescribing as part of a shared care agreement, after specialists have assessed patients and initiated treatment with cannabis based products, would improve patients’ access to products, allow a more holistic approach to care, and may reduce costs to the NHS, says NICE.
The guideline was fast tracked after cannabis based products were reclassified last year to allow specialist doctors to prescribe them in exceptional cases where patients’ clinical needs could not be met by licensed drugs.1
The only licensed cannabis based drug that NICE recommends is nabilone as an add-on treatment for adults with nausea and vomiting induced by chemotherapy whose symptoms have not responded to conventional drugs. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.